OverTheCounterToday

This Week In OTCs And Nutritionals: FDA Supplement Enforcement, P&G Price Hike, Perrigo Q1

"The Tan Sheet" this week reports on FDA's supplement enforcement priorities with a dispatch from the Council for Responsible Nutrition's recent conference. FDA's Division of Dietary Supplement Programs plans enforcement activity in the areas of new dietary ingredients, good manufacturing practices and adverse event reporting. Also from the CRN conference, a story on what retailers expect to see from supplements and OTCs in the areas of social media marketing and consumer education.

Our Oct. 31 issue keeps pace with the flurry of quarterly earnings reports. In addition to news on Procter & Gamble's planned across-the-board price increase and Perrigo's underperforming OTCs and nutritionals, we've got highlights from Bayer, Colgate-Palmolive, GlaxoSmithKline, Mead Johnson Nutrition and many other reporting companies.

As always, there's plenty more in the latest "Tan Sheet," including a look at how FDA might learn from Health Canada's revised probiotics regulations, scrutiny of Allegra's allergy relief claims, and industry's defense of spray sunscreen safety.    

 

Make "The Tan Sheet" your go-to weekly source for OTC and nutritional news and analysis. For information on a free 30-day trial subscription, click here.

Also, follow "The Tan Sheet" on Twitter and Facebook.

This Week In OTCs And Nutritionals: 'Tis The Earnings Season

Big names across the realm of OTC drugs and nutritionals are reporting quarterly sales and earnings this week, including GlaxoSmithKline, Mead Johnson, Merck, Perrigo, Procter & Gamble, USANA Health Sciences and Vitamin Shoppe. Check out "The Tan Sheet" Oct. 31 for coverage of these companies and more.

In the meantime, our Oct. 24 issue reviewed Johnson & Johnson's third quarter results, reported Oct. 18. See the full story below.

And for more OTC/nutritional news and insights, sign up for a free 30-day trial subscription to "The Tan Sheet" by clicking here. We're also on Twitter and Facebook. 

 

This Week In OTCs And Nutritionals: Switch, GMPs, Abbott

The Oct. 24 issue of “The Tan Sheet” reports on researchers’ recommendations for sponsors of OTC switch applications based on questions FDA has asked in previous switches, as well as additional news in the OTC sector from firms including Johnson & Johnson and Help Remedies.

We also note that for the first time, FDA submitted GMP warning letters with language explaining the agency considers own-label dietary supplement marketers responsible for their contract manufacturers’ violations. Plus, we look at how Abbott Laboratories’ nutrition business gains importance with the firm’s plan to spin off its research-based branded pharmaceuticals business.

Make "The Tan Sheet" your go-to weekly source for OTC and nutritional news and analysis. For information on a 30-day free trial subscription, click here.

Also, follow "The Tan Sheet" on Twitter and Facebook.

This Week In OTCs And Nutritionals: The Supplement Industry Challenges Research And CHPA Workshop Features Quality Control, Switch Discussions

The supplement industry takes one on the chin, but keeps fighting after several studies spotlight the risks of supplements and suggest additional regulation may be needed. Supplement firm Herbalife also asks FDA to meet the industry half-way in the debate about what the new dietary ingredient notification process covers.

On the OTC side, FDA and drug industry leaders brainstorm best practices to improve quality control and ways to facilitate switch at the Consumer Healthcare Products Association’s Product Quality & Operations Workshop.

This news preview is brought to you by "The Tan Sheet," your source for the most in-depth news and analysis from the world of OTC drugs and nutritionals. For information on a 30-day free trial subscription, click here.

Also, follow "The Tan Sheet" on Twitter and Facebook.

"The Tan Sheet" News Roundup: J&J Tops Forbes Brand Rankings, Studies Question Supplements, Pryor Re-tries Nanotech Bill

This news roundup is brought to you by "The Tan Sheet," your source for the most in-depth news and analysis from the world of OTC drugs and nutritionals. For information on a 30-day free trial subscription, click here.

Also, check out "The Tan Sheet" on Twitter and Facebook.

This Week In OTCs And Nutritionals: Silenor On Switch Path, FTC Claim Standards, New Supplement Trade Group

 
"The Tan Sheet" examines the Rx-to-OTC switch potential of Somaxon Pharmaceuticals' Silenor (doxepin), a sleep aid that could launch OTC in five to seven years, pending safety and efficacy studies. Procter & Gamble has co-marketing rights to Rx Silenor through the end of 2011 and appears a likely candidate to ultimately license a nonprescription version from Somaxon.

Our Oct. 10 issue has coverage from the National Advertising Division's annual conference, at which Federal Trade Commission consumer protection official David Vladeck spoke on claim substantiation standards. "The Tan Sheet" this week also takes a look at the nascent dietary supplement trade association formed by Jarrow Formulas President Jarrow Rogovin, who promises "more creative" and more aggressive industry representation.

Additionally, we've got stories on Garden of Life's latest faceoff with FTC, Matrixx Initiatives' settlement with shareholders over its private-equity buyout, and what's holding up FDA's food safety user fees program.

 

This news preview is brought to you by "The Tan Sheet," your source for the most in-depth news and analysis from the world of OTC drugs and nutritionals. For information on a 30-day free trial subscription, click here.

Also, follow "The Tan Sheet" on Twitter this week at SupplySide West in Las Vegas.

This Week In OTCs And Nutritionals: J&J/Merck JV Dissolves, Spiked Supplement Indictments, CHPA On Sunscreen

This week's issue of "The Tan Sheet" looks at Merck's strategy behind exiting its 22-year-old consumer products joint venture with Johnson & Johnson. Merck now will have more flexibility to pursue Rx-to-OTC switches of drugs such as Clarinex for allergies and Zetia for cholesterol, while J&J takes sole ownership of digestive health OTCs Pepcid, Mylanta and Mylicon.

On the inside of our Oct. 3 edition, we delve into an FDA-assisted investigation into a founder of Utah nutritional ingredient supplier NovaCare and the indictments resulting from charges linked to product adulteration. "The Tan Sheet" also examines the Consumer Healthcare Products Association's comments to FDA on the agency's proposal to cap sunscreen SPF labeling at 50.

Elsewhere in this week's issue, we've got stories on FDA's time and extent application guidance, future trends in the weight-loss market and why supplement marketers should consider online video as part of their strategy.

 

This news preview is brought to you by "The Tan Sheet," your source for the most in-depth news and analysis from the world of OTC drugs and nutritionals. For information on a 30-day free trial subscription, click here.

Also, follow "The Tan Sheet" on Twitter and Facebook.